Literature DB >> 10783480

Involvement of polyglutamine endolysis followed by pyroglutamate formation in the pathogenesis of triplet repeat/polyglutamine-expansion diseases.

T C Saido1.   

Abstract

The mechanism by which polyglutamine expansions in several proteins lead to neurodegenerative disorders remains largely unknown. The biochemical properties of polyglutamine repeats suggest one possible explanation; endolytic cleavage at a glutaminyl-glutaminyl bond followed by pyroglutamate formation may contribute to the pathogenesis through augmenting the catabolic stability, hydrophobicity, amyloidogenicity, and neurotoxicity of the polyglutaminyl proteins. The hypothesis points out novel therapeutic strategies to delay disease onset in genetically diagnosed presymptomatic patients. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783480     DOI: 10.1054/mehy.1999.0866

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  siRNA screen identifies QPCT as a druggable target for Huntington's disease.

Authors:  Michael Hannus; Birte Sönnichsen; Sara Imarisio; Angeleen Fleming; Maria Jimenez-Sanchez; Wun Lam; Alessia Tarditi; Fiona Menzies; Teresa Ed Dami; Catherine Xu; Eduardo Gonzalez-Couto; Giulia Lazzeroni; Freddy Heitz; Daniela Diamanti; Luisa Massai; Venkata P Satagopam; Guido Marconi; Chiara Caramelli; Arianna Nencini; Matteo Andreini; Gian Luca Sardone; Nicola P Caradonna; Valentina Porcari; Carla Scali; Reinhard Schneider; Giuseppe Pollio; Cahir J O'Kane; Andrea Caricasole; David C Rubinsztein
Journal:  Nat Chem Biol       Date:  2015-04-06       Impact factor: 15.040

2.  Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.

Authors:  Andreas Becker; Stephanie Kohlmann; Anca Alexandru; Wolfgang Jagla; Fabio Canneva; Christoph Bäuscher; Holger Cynis; Reinhard Sedlmeier; Sigrid Graubner; Stephan Schilling; Hans-Ulrich Demuth; Stephan von Hörsten
Journal:  BMC Neurosci       Date:  2013-10-01       Impact factor: 3.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.